Welcome to the latest issue of Pharmaceutical Technology Focus magazine

This month’s cover story is the first in a two-part deep dive where we investigate the world of priority review vouchers—an FDA scheme that has grown in leaps and bounds in the last few years. In recent times, pharma companies have spent tens of millions of dollars, and sometimes even more than $100m, to purchase a single fast-track ticket to approval, and the story explains how small biotechs may benefit the most from such programmes.

Also in this issue, we touch upon the growing awareness among pharmaceutical manufacturers regarding sustainability and how they can change their current practices to better protect the environment for the future.

Don’t miss a feature on the latest advances in cancer vaccines, an interview that delves into the rise of fraudulent anti-obesity drugs, and more.

All this and the latest news and analysis on the pharmaceutical and biotech industry.

Manasi Vaidya, editor

Go to article: Home | Inside the world of priority review vouchers where time is moneyGo to article: Editor's letterGo to article: ContentsGo to article: Mimotopes Company InsightGo to article: MimotopesGo to article: BriefingGo to article: News in NumbersGo to article: Latest NewsGo to article: Latest DealsGo to article: Project UpdatesGo to article: Trends & InsightGo to article: Molnar-Institute Company InsightGo to article: Molnar-InstituteGo to article: Lactalis IngredientsGo to article: In DepthGo to article: Inside the world of priority review vouchers where time is money Go to article: Quality and sustainability: The balancing act for pharma manufacturingGo to article: 2023 in review: Cancer vaccines dose up on advances with tailored approachesGo to article: Diversity and ePROs: Still siloed concepts in the era of DCTs? Go to article: Q&A: Tackling the rise of fake anti-obesity drugs on the market Go to article: Patching the problem of EU drug shortagesGo to article: Out-of-spec cell therapy manufacturing: an ethical dilemma for CDMOs and doctorsGo to article: NiproGo to article: phasetwoGo to article: Thematic TakeGo to article: Thematic Take: contentsGo to article: Foreword: What’s next for the Internet of ThingsGo to article: An introduction to the Internet of Things Go to article: The digital ecosystem of the IoTGo to article: Timeline: Internet of ThingsGo to article: The impact of IoT on the pharma industry Go to article: Applications of IoT in the pharma industryGo to article: Latest news: IoT in pharmaGo to article: Analyst Q&A: IoT in pharmaGo to article: Bupa leverages unique position to develop IoT and AI features Go to article: IoT innovation: Leading companies in microneedles for transdermal drug deliveryGo to article: IoT in the pharmaceutical industry: analysing innovation, investment and hiring trendsGo to article: GlobalData Thematic IntelligenceGo to article: Sponsored SupplementsGo to article: Avenga Company InsightGo to article: ListingsGo to article: EventsGo to article: Innovation RankingsGo to article: Buyer's GuidesGo to article: Next issue